Nerteley Quaye

Learn More
Treatment of gonorrhoea is threatened by antimicrobial resistance, and decreased susceptibility and resistance to recommended therapies is emerging in Europe. Current associations between resistance and molecular type remain poorly understood. Gonococcal isolates (n=1,066) collected for the 2009 and 2010 European Gonococcal Antimicrobial Surveillance(More)
OBJECTIVES The objective of this study was to investigate the genetic diversity of blaTEM alleles, antimicrobial susceptibility and molecular epidemiological characteristics of penicillinase-producing Neisseria gonorrhoeae (PPNG) isolates collected in 2012 from England and Wales. METHODS PPNG isolates were from the 2012 Gonococcal Resistance to(More)
OBJECTIVES There is a need for new or alternative antimicrobial agents for the treatment of gonorrhoea as antimicrobial resistance emerges to current therapies. The aim was to investigate the activity of ertapenem against isolates of Neisseria gonorrhoeae with decreased susceptibility to cefixime. METHODS A panel of 52 clinical isolates and 10 control(More)
OBJECTIVES Reference laboratories are increasingly using more sensitive rapid molecular techniques, such as nucleic acid amplification tests (NAATs), to diagnose infections with Neisseria gonorrhoeae. We determined the proportion of patients at sentinel genitourinary medicine clinics in England whose NAAT-positive diagnoses were also culture-positive for N.(More)
OBJECTIVES The emergence of decreased susceptibility to third-generation, extended-spectrum cephalosporins in Neisseria gonorrhoeae and associated treatment failures highlights the need to consider alternatives for future therapeutic use, such as gentamicin. METHODS The three laboratories surveying gonococcal antimicrobial susceptibility as part of the(More)
OBJECTIVES Treatment of Neisseria gonorrhoeae is threatened by the emergence of antimicrobial resistance. We analysed data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales to identify groups most at risk of reduced susceptibility to the currently recommended first-line therapy, ceftriaxone. METHODS Data(More)
  • 1